Friday 6-6-2014 Merck & Company (MRK) $MRK opened
Post# of 151
Posted On: 06/08/2014 10:42:36 PM
Friday 6-6-2014 Merck & Company (MRK) $MRK opened at 58.20 hitting the high price of 58.26 and a day low of 57.68 with a total volume of 6,703,200. MRK had a previous close of 58.10 and has been seeing an average volume of 7,969,135.
Overall Average: 80% Buy
Recent stock forum discussions about MRK http://investorshangout.com/search?q=MRK&...mp;yt0=Go!
3 Pharma Giants Battling for Immuno-Oncology Dominance
Eric Thomasson, The Motley Fool - Motley Fool - Fri Jun 06, 5:00PM CDT
Cancer drugs have been taking center stage in recent months. Some of the drugs making the biggest headlines come from the field of immuno-oncology, which are drugs that manipulate the body's immune system in an effort to fight cancer. Three... (full story)
The Dow Sets Another Record, But Why Are Pharma Stocks Falling?
Dan Caplinger, The Motley Fool - Motley Fool - Fri Jun 06, 3:30PM CDT
The Dow Jones Industrials set another all-time high on Friday, rising nearly 88 points and marking the eighth time the index has hit unprecedented levels this year. The catalyst for today's spike was the May employment report from the Labor... (full story)
Is AstraZeneca Making a Big Mistake With Its Pipeline?
Brian Orelli, The Motley Fool - Motley Fool - Fri Jun 06, 1:30PM CDT
AstraZeneca recently published some interesting data on the progress of its pipeline from 2005 to 2010, highlighting just how difficult it is to get a drug through the marathon of clinical trials. For the industry as a whole, just 6% of drugs in... (full story)
Hospital-Acquired Infection Control Market - Sterilization, Disinfection, Testing and Treatment
M2 - Fri Jun 06, 8:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c5k8z3/the_market_for) has announced the addition of the "The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment)" report to their offering. This Kalorama Information report The Market for Hospital-Acquired Infection Control (Sterilization, Cleaning, Testing, Treatment) focuses on the market for preventing, testing and treating infections in the healthcare environment. Given the cost of hospital-acquired and healthcare-associated infections (HAIs), demand has increased for solutions that can help the healthcare industry reduce infections and the costs associated with them. The U.S. Centers for Disease Control and Prevention (CDC) estimates that around 1 in 20 or 5% of hospitalized patients will contract an HAI. Treatment and testing guidelines for the following diseases are covered: - Acinetobacter Baumannii - Clostridium Difficile - Hospital-Acquired Pneumonia - Pseudomonas Aeruginosa - Staphylococcus Aureus - Methicillin-resistant Staphylococcus Aureus (MRSA) - Vancomycin-Intermediate/Resistant Staphylococcus Aureus - Tuberculosis - Urinary Tract Infections - Vancomycin-resistant Enterococcus - Ventilator-Associated Pneumonia Companies included in this report are: - Advanced Sterilization Products - Becton Dickinson - Belimed AG - bioMerieux - Cantel - Cepheid - Getinge - Kimberly-Clark - Merck & Co. - Nordion - Pfizer - Roche - Sakura Seiki - Steris - TSO3 Key Topics Covered: Chapter One: Executive Summary Chapter Two: Introduction And Industry Trends Chapter Three: Infection Prevention Chapter Four: Infection Testing Chapter Five: Infection Treatment Chapter Six: Market Opportunities For Hospital-Acquired Infection Control Chapter Seven: Company Profiles For more information visit http://www.researchandmarkets.com/research/c5...market_for (full story)
Is Bristol-Myers Squibb's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Fri Jun 06, 8:30AM CDT
Bristol-Myers Squibb is one of the globe's top drugmakers and a staple in dividend investors' portfolios. Big drug companies such as Bristol-Myers, Johnson & Johnson , and Merck offer investors predictable, dividend-boosting revenue... (full story)
The World Market for Biosimilars 2013-2017 - EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies
M2 - Fri Jun 06, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7brbq6/the_world_market) has announced the addition of the "The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition" report to their offering. The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following: - Scientific Differences of Pharmaceuticals and Biopharmaceuticals - Market Share of Biosimilar Sales in Comparison to Brand Sales - Marketed Biologics with Expired Patents - Marketed Biologics with Active Patents - Cost Savings From Biosimilar Use - World Biosimilar Market Potential by Region 2010-2017 - World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other) - Biosimilars Pipeline by Company and Product Type As part of its coverage, the following companies were profiled: - 3SBio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Bio Sidus S.A. - BioXpress Therapeutics S.A. - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy's Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals USA, - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance GeneMedix PLC - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International GmbH - STADA Arzneimittel AG - TEVA Pharmaceutical Industries, Ltd. - Wockhardt Ltd. - Xiamen Amoytop Biotech Co Ltd. For more information visit http://www.researchandmarkets.com/research/7b...rld_market (full story)
Vaccines 2014-2020: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments (Influenza, Cervical Cancer, Combinations, Hepatitis, Pneumococcal, MMR, Varicella, Poliovirus, HIB, Others)
M2 - Fri Jun 06, 8:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fm23b8/vaccines_2014) has announced the addition of the "Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments (Influenza, Cervical Cancer, Combinations, Hepatitis, Pneumococcal, MMR, Varicella, Poliovirus , HIB, Others)" report to their offering. Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments The global market for human vaccines experienced strong growth through 2013 with the introduction of new vaccines. These new products and other trends are well-covered in Vaccines: The World Market. The Kalorama information report examines the global market for vaccines, covering specifically commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable. Vaccination protects not only individuals, but also entire communities from diseases spread by person-to-person transmission. The high growth rates and successful launch of several recent products have kept interest in the global vaccine market high. This report investigates the changes vaccine manufacturers have undergone in the past year, providing world market analysis, identifying the key players, and outlining critical trends in this fast-changing industry. Included in this report are current market size and forecasts to 2020 for the following vaccines: - Pediatric Vaccines - Pneumococcal - Combinations - Varicella - MMR - Poliovirus - Hepatitis - HIB - Other Pediatric - Adult Vaccines: - Influenza - Cervical Cancer - Hepatitis - Pneumococcal - Travel; DT; Misc. Key Topics Covered: - Executive Summary - Introduction To Vaccines - Pediatric Preventive Vaccines - Adult Preventive Vaccines - Vaccines Market Summary - Issues And Trends - Company Profiles - AlphaVax, Inc. - Bavarian Nordic A/S - Baxter Healthcare - Bharat Biotech - Crucell /Johnson & Johnson - Emergent biosolutions - GlaxoSmithKline - Medimmune - Merck & Co. Inc - Novartis - Pfizer - Sanofi Pasteur For more information visit http://www.researchandmarkets.com/research/fm...cines_2014 About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. (full story)
MSD to Present New Clinical Data on Sitagliptin, Investigational Omarigliptin, and Real-World Data in Patients with Type 2 Diabetes at the 74th Scientific Sessions of the American Diabetes Association
Business Wire - Fri Jun 06, 7:00AM CDT
MSD, known as Merck (NYSE:MRK) in the United States and Canada, will present 13 new studies and analyses, including data for its DPP-4 inhibitor JANUVIA(R) (sitagliptin) and for its investigational once-weekly DPP-4 inhibitor omarigliptin, at the 74th Scientific Sessions of the American Diabetes Association (ADA) being held in San Francisco, June 13-17, 2014. (full story)
Merck to Present New Clinical Data on JANUVIA(R) (Sitagliptin), Investigational Omarigliptin, and Real-World Data in Patients with Type 2 Diabetes at the 74th Scientific Sessions of the American Diabetes Association
Business Wire - Fri Jun 06, 7:00AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, will present 13 new studies and analyses, including data for its DPP-4 inhibitor JANUVIA(R) (sitagliptin) and for its investigational once-weekly DPP-4 inhibitor omarigliptin, at the 74th Scientific Sessions of the American Diabetes Association (ADA) being held in San Francisco, June 13-17, 2014. (full story)
Global Phenylketonuria (PKU) Clinical Trials Report 2014
M2 - Fri Jun 06, 4:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jnxg8w/phenylketonuria) has announced the addition of the "Phenylketonuria (PKU) Global Clinical Trials Review, H1, 2014" report to their offering. Phenylketonuria (PKU) Global Clinical Trials Review, H1, 2014" provides data on the Phenylketonuria (PKU) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Phenylketonuria (PKU). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Phenylketonuria (PKU). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - BioMarin Pharmaceutical Inc. - E. Merck KG - Emory University - University of Leipzig - Washington University School of Medicine - University of Miami - University of Southern California - Ludwig-Maximilians-Universitat Munich - The University of Texas Health Science Center at Houston - Hamilton Health Sciences - University Hospital, Tours - University of Missouri For more information visit http://www.researchandmarkets.com/research/jn...lketonuria (full story)
2 Reasons to Watch Amgen, Inc.
Cory Renauer, The Motley Fool - Motley Fool - Thu Jun 05, 5:30PM CDT
Amgen is looking at two great opportunities. The company's brightest immune-oncology prospect is giving mixed results on its own, but a valuable partnership seems likely. In the race to produce a next-generation cholesterol reducer, high marks from... (full story)
First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily Dosing Regimen of ISENTRESS(R) (raltegravir)
Business Wire - Thu Jun 05, 4:00PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in the company's global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a once-daily investigational formulation of ISENTRESS(R) (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-naive HIV-1-infected adults. ISENTRESS film-coated tablets are currently administered twice daily in accordance with the approved Prescribing Information. (full story)
$100 million NuvaRing settlement finalized
By JIM SALTER - AP - Thu Jun 05, 1:44PM CDT
ST. LOUIS (AP) — A $100 million settlement involving NuvaRing, a birth-control device linked to sometimes-fatal side effects, will stand now that the vast majority of claimants have chosen to opt into the agreement, those involved in the lawsuits said Thursday. (full story)
Merck (MRK) Breaks Through Resistance at $58.12
Comtex SmarTrend(R) - Thu Jun 05, 10:49AM CDT
Shares of Merck (NYSE:MRK) opened today above their pivot of $57.82 and have already reached the first level of resistance at $58.12. Should the shares continue to rise, the resistance pivots of $58.32 and $58.82 will be of interest. (full story)
Germany 2014 Wealth Book - Insights into the $4.2 Trillion Market
M2 - Thu Jun 05, 10:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ls23jl/germany_2014) has announced the addition of the "Germany 2014 Wealth Book" report to their offering. This report is the result of extensive research covering the high net worth individual (HNWI) population and wealth management market in Germany. This report reviews the performance and asset allocations of HNWIs and Ultra-HNWIs in Germany. It also includes an evaluation of the local wealth management market. Scope - Independent market sizing of Germany HNWIs across five wealth bands - HNWI volume, wealth and allocation trends from 2009 to 2013 - HNWI volume, wealth and allocation forecasts to 2018 - HNWI and UHNWI asset allocations across 13 asset classes - Geographical breakdown of all foreign assets - Alternative breakdown of liquid vs. investable assets - Number of UHNWIs in major cities - Number of wealth managers in each city - City wise ratings of wealth management saturation and potential - Details of the development, challenges and opportunities of the Wealth Management and Private Banking sector in Germany - Size of the German wealth management industry - Largest private banks by AuM - Detailed wealth management and family office information - Insights into the drivers of HNWI wealth Key Highlights - There were 1,382,265 HNWIs in Germany in 2013. These HNWIs held US$4.2 trillion in wealth, and wealth per HNWI was US$3,038,491. - In 2013, German HNWI numbers increased by 4.2%, following a 5.7% decrease in 2012. - Growth in HNWI wealth and volumes is expected to improve over the forecast period. The number of German HNWIs is forecast to grow by 11%, reaching 1,561,820 by 2018, and HNWI wealth is expected to grow by 25%, reaching US$5.60 trillion by 2018. - At the end of 2013, German HNWIs held 34.6% (US$1.5 trillion) of their wealth outside their home country, which is higher than the worldwide average of 20-30%. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Wealth Sector Fundamentals 4 Findings from the WealthInsight HNWI Database 5 Analysis of German HNWI Investments 6 Competitive Landscape of the Wealth Sector 7 Appendix Companies Mentioned - BHF-Bank Private Banking - Bankhaus Lampe - Berenberg Private Banking - Commerzbank Private Banking - DZ Privatbank - Deutsche Bank Private Wealth Management - Merck Finck & Co. - Mertzler Private Banking - UniCredit Bank AG For more information visit http://www.researchandmarkets.com/research/ls...rmany_2014 (full story)
Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany
M2 - Thu Jun 05, 9:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4jll46/glioblastoma) has announced the addition of the "Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany" report to their offering. During the 2012-2019 forecast period, the GBM market is expected to grow rapidly from $305m to $583m. Due to the poor prognosis under currently available treatments, therapies with high potency are in strong demand in the Glioblastoma Multiforme (GBM) market. In newly diagnosed patients, the current standard of care, comprising resection surgery, radiation therapy and chemotherapy with Merck's Temodar (temozolomide), has a maximum Overall Survival (OS) of 15 months and almost inevitable tumor recurrence. Current therapeutic options for recurrent GBM are Roche's Avastin (bevacizumab), carmustine and other chemotherapy drugs used off-label. However, they only offer limited OS benefit, leaving high unmet need in this patient segment. The market entry of Northwest Biotherapeutics' DCVax-L, a dendritic cell-based therapeutic vaccine that acts as an add-on to the standard treatment in newly diagnosed patients, will account for much of this growth. Having demonstrated superior OS improvement compared with the standard treatment alone in clinical trials, it is expected to bear high market potential, given that its efficacy is translated into larger Phase III trials. The cancer vaccine Rindopepimut (CDX-110) and targeted therapy Cotara will also enter the GBM market, but will drive growth to a lesser extent. However, unmet needs are likely to remain in the relapsed setting over the forecast period due to the lack of superior OS benefits in the late-stage pipeline. Scope - A brief introduction to GBM, including the disease pathogenesis, risk factors and diagnosis - In-depth analysis of the drugs available for the treatment of GBM, including safety, efficacy, treatment patterns, and strengths and weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy - A comprehensive review of the developmental pipeline for GBM, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period, with the pipeline analyzed by Phase distribution, molecule type and molecular target - Additional in-depth analysis of GBM clinical trials by Phase, molecule type, trial size, trial duration and program failure rate - Multi-scenario forecast data for the GBM market to 2019, taking into account the introduction of new drugs, the expiry of key patents and the changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain - Discussion of the drivers of and barriers to market growth - Discussion of the licensing and co-development deals landscape in GBM Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed drugs - Temodar (temozolomide) - Merck - Avastin (bevacizumab) - Roche - BiCNU (carmustine) and Gliadel Wafer (carmustine in polifeprosan) - BiCNU (carmustine) - Bristol-Myers Squibb - Gliadel Wafer (carmustine in polifeprosan) - Eisai - Lomustine - Carboplatin - Cyclophosphamide - Etoposide - Irinotecan 4 Glioblastoma Pipeline - DCVax-L - Northwest Biotherapeutics - Rindopepimut (CDX-110) - Celldex Therapeutics - Avastin (bevacizumab)- Roche - ICT-107 - ImmunoCellular Therapeutics - Cotara- Peregrine Pharmaceuticals - Eir-060- EirGen Pharma - Heat Map of Safety and Efficacy and Competitor Matrix for Glioblastoma Multiforme Pipeline 5 Market forecasts 6 Deals and Strategic Consolidations - Del Mar Pharmaceuticals Enters into Agreement with Guangxi Wuzhou Pharmaceutical - Immatics Biotechnologies Enters into Agreement with Cancer Research UK - ImmunoCellular Therapeutics Enters into Agreement with University of Pennsylvania - Bexion Pharmaceuticals Enters into Agreement with Cincinnati Children's Hospital Medical Center - Celldex Therapeutics Enters into Agreement with Duke University Brain Tumor Cancer Center 7 Appendix For more information visit http://www.researchandmarkets.com/research/4j...ioblastoma (full story)
Antihypertensive Therapeutics in Major Developed Markets to 2020 - Market to Decline due to Key Patent Expiries
M2 - Thu Jun 05, 9:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tgc6l9/antihypertensive) has announced the addition of the "Antihypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries" report to their offering. Market to Decline due to Key Patent Expiries The global anti-hypertensives market is expected to decline during the forecast period at a negative Compound Annual Growth Rate (CAGR) of 0.9% from $40 billion in 2013 to $37.6 billion in 2020, with growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline thereafter. The initial growth will be due to the increased penetration of fixed-dose combination drugs (Amturnide, Exforge Tribenzor, Azor, Tekturna HCT, Edarbyclor, Twynsta, Benicar HCT, Micardis Plus, Tekamlo, Valturna), a rise in the prevalence population from 181 million to 190 million at a CAGR of 0.6%, and two new expected launches in the pipeline (azilsartan amlodipine, and AHU377 valsartan). However, due to the expiry of the exclusivity of major drugs both before and during the forecast period (Cozaar in 2010; Diovan, Avapro and Atacand in 2012; Exforge in 2014; Benicar in 2016; and Tekturna and Tekturna HCT in 2018), increased generic penetration and a low diagnosis rate, the market will decline from 2017. Hypertension is a chronic disease and so its management required prolonged treatment. The management of hypertension requires prolonged treatment as it is a chronic disease, ultimately ensuring market stability despite generic erosion. Anti-Hypertensives Pipeline: Limited Scope Most of the drugs in the anti-hypertensives pipeline are generics (77%), and only 20% of molecules are novel drug candidates. The novel approach is limited to a few targets such as nondihydropyridine dual L/T-type calcium channel blockers (ACT-280778), Rho-associated kinase inhibitors (AN-3485), and vitamin D receptor agonists (CARD-024), to name a few. Novartis' AHU-377, a novel molecule that functions as a Neutral Endopeptidase Inhibitor (NEP), is currently in Phase III as a combination drug with Novartis' blockbuster valsartan. Most of the drug dosages in the anti-hypertension market comprise one oral tablet once daily. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed Products 4 Product Pipeline 5 Market Forecast 6 Deals and Strategic Consolidations 7 Appendix Companies Mentioned - Boehringer Ingelheim - Daiichi Sankyo - Merck - Novartis - Pfizer - Speedel For more information visit http://www.researchandmarkets.com/research/tg...pertensive (full story)
NuvaRing Lawsuit Attorneys at The Oliver Law Group Comment on CNN Investigation into Alleged NuvaRing Side Effects
PRWeb - Wed Jun 04, 10:31PM CDT
The NuvaRing lawsuit attorneys at The Oliver Law Group note that CNN will air a series of investigative reports detailing the serious, and potentially deadly side effects, allegedly suffered by young women who have used the NuvaRing vaginal ring birth control device. According to an article which appeared in the Durango Herald on June 2, 2014, the series of broadcasts will air during Anderson360, and will feature the family of one young woman who allegedly died after suffering a blood clot brought on by NuvaRing. The young woman's family is now pursuing a NuvaRing lawsuit against Merck & Co., the manufacturer of the contraceptive ring. [cnn.com/video/data/2.0/video/us/2014/06/01/nr-dnt-nuvaring-investigation.cnn.html , CNN June 1, 2014] [durangoherald.com/article/20140602/NEWS01/140609932/-1/taxonomy/Parents-of-young-woman-to-appear-on-CNN-, Durango Herald, June 2, 2014] (full story)
ASCO: Bristol-Myers Squibb and Merck Don't Disappoint
Brian Orelli, The Motley Fool - Motley Fool - Wed Jun 04, 6:38PM CDT
We knew going into American Society of Clinical Oncology annual meeting that immuno-oncology would be a big focus. And Bristol-Myers Squibb and Merck didn't disappoint. Rather than attacking the tumor directly, immuno-oncology drugs encourage... (full story)
Is Merck's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Wed Jun 04, 5:00PM CDT
Merck is one of the world's biggest drugmakers and is a staple in dividend investors' portfolios. That's because pharmaceutical companies such as Merck, Johnson & Johnson , and Bristol-Myers Squibb offer investors a steady (and... (full story)
Overall Average: 80% Buy
Recent stock forum discussions about MRK http://investorshangout.com/search?q=MRK&...mp;yt0=Go!
3 Pharma Giants Battling for Immuno-Oncology Dominance
Eric Thomasson, The Motley Fool - Motley Fool - Fri Jun 06, 5:00PM CDT
Cancer drugs have been taking center stage in recent months. Some of the drugs making the biggest headlines come from the field of immuno-oncology, which are drugs that manipulate the body's immune system in an effort to fight cancer. Three... (full story)
The Dow Sets Another Record, But Why Are Pharma Stocks Falling?
Dan Caplinger, The Motley Fool - Motley Fool - Fri Jun 06, 3:30PM CDT
The Dow Jones Industrials set another all-time high on Friday, rising nearly 88 points and marking the eighth time the index has hit unprecedented levels this year. The catalyst for today's spike was the May employment report from the Labor... (full story)
Is AstraZeneca Making a Big Mistake With Its Pipeline?
Brian Orelli, The Motley Fool - Motley Fool - Fri Jun 06, 1:30PM CDT
AstraZeneca recently published some interesting data on the progress of its pipeline from 2005 to 2010, highlighting just how difficult it is to get a drug through the marathon of clinical trials. For the industry as a whole, just 6% of drugs in... (full story)
Hospital-Acquired Infection Control Market - Sterilization, Disinfection, Testing and Treatment
M2 - Fri Jun 06, 8:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c5k8z3/the_market_for) has announced the addition of the "The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment)" report to their offering. This Kalorama Information report The Market for Hospital-Acquired Infection Control (Sterilization, Cleaning, Testing, Treatment) focuses on the market for preventing, testing and treating infections in the healthcare environment. Given the cost of hospital-acquired and healthcare-associated infections (HAIs), demand has increased for solutions that can help the healthcare industry reduce infections and the costs associated with them. The U.S. Centers for Disease Control and Prevention (CDC) estimates that around 1 in 20 or 5% of hospitalized patients will contract an HAI. Treatment and testing guidelines for the following diseases are covered: - Acinetobacter Baumannii - Clostridium Difficile - Hospital-Acquired Pneumonia - Pseudomonas Aeruginosa - Staphylococcus Aureus - Methicillin-resistant Staphylococcus Aureus (MRSA) - Vancomycin-Intermediate/Resistant Staphylococcus Aureus - Tuberculosis - Urinary Tract Infections - Vancomycin-resistant Enterococcus - Ventilator-Associated Pneumonia Companies included in this report are: - Advanced Sterilization Products - Becton Dickinson - Belimed AG - bioMerieux - Cantel - Cepheid - Getinge - Kimberly-Clark - Merck & Co. - Nordion - Pfizer - Roche - Sakura Seiki - Steris - TSO3 Key Topics Covered: Chapter One: Executive Summary Chapter Two: Introduction And Industry Trends Chapter Three: Infection Prevention Chapter Four: Infection Testing Chapter Five: Infection Treatment Chapter Six: Market Opportunities For Hospital-Acquired Infection Control Chapter Seven: Company Profiles For more information visit http://www.researchandmarkets.com/research/c5...market_for (full story)
Is Bristol-Myers Squibb's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Fri Jun 06, 8:30AM CDT
Bristol-Myers Squibb is one of the globe's top drugmakers and a staple in dividend investors' portfolios. Big drug companies such as Bristol-Myers, Johnson & Johnson , and Merck offer investors predictable, dividend-boosting revenue... (full story)
The World Market for Biosimilars 2013-2017 - EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies
M2 - Fri Jun 06, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7brbq6/the_world_market) has announced the addition of the "The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition" report to their offering. The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following: - Scientific Differences of Pharmaceuticals and Biopharmaceuticals - Market Share of Biosimilar Sales in Comparison to Brand Sales - Marketed Biologics with Expired Patents - Marketed Biologics with Active Patents - Cost Savings From Biosimilar Use - World Biosimilar Market Potential by Region 2010-2017 - World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other) - Biosimilars Pipeline by Company and Product Type As part of its coverage, the following companies were profiled: - 3SBio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Bio Sidus S.A. - BioXpress Therapeutics S.A. - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy's Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals USA, - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance GeneMedix PLC - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International GmbH - STADA Arzneimittel AG - TEVA Pharmaceutical Industries, Ltd. - Wockhardt Ltd. - Xiamen Amoytop Biotech Co Ltd. For more information visit http://www.researchandmarkets.com/research/7b...rld_market (full story)
Vaccines 2014-2020: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments (Influenza, Cervical Cancer, Combinations, Hepatitis, Pneumococcal, MMR, Varicella, Poliovirus, HIB, Others)
M2 - Fri Jun 06, 8:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fm23b8/vaccines_2014) has announced the addition of the "Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments (Influenza, Cervical Cancer, Combinations, Hepatitis, Pneumococcal, MMR, Varicella, Poliovirus , HIB, Others)" report to their offering. Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments The global market for human vaccines experienced strong growth through 2013 with the introduction of new vaccines. These new products and other trends are well-covered in Vaccines: The World Market. The Kalorama information report examines the global market for vaccines, covering specifically commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable. Vaccination protects not only individuals, but also entire communities from diseases spread by person-to-person transmission. The high growth rates and successful launch of several recent products have kept interest in the global vaccine market high. This report investigates the changes vaccine manufacturers have undergone in the past year, providing world market analysis, identifying the key players, and outlining critical trends in this fast-changing industry. Included in this report are current market size and forecasts to 2020 for the following vaccines: - Pediatric Vaccines - Pneumococcal - Combinations - Varicella - MMR - Poliovirus - Hepatitis - HIB - Other Pediatric - Adult Vaccines: - Influenza - Cervical Cancer - Hepatitis - Pneumococcal - Travel; DT; Misc. Key Topics Covered: - Executive Summary - Introduction To Vaccines - Pediatric Preventive Vaccines - Adult Preventive Vaccines - Vaccines Market Summary - Issues And Trends - Company Profiles - AlphaVax, Inc. - Bavarian Nordic A/S - Baxter Healthcare - Bharat Biotech - Crucell /Johnson & Johnson - Emergent biosolutions - GlaxoSmithKline - Medimmune - Merck & Co. Inc - Novartis - Pfizer - Sanofi Pasteur For more information visit http://www.researchandmarkets.com/research/fm...cines_2014 About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. (full story)
MSD to Present New Clinical Data on Sitagliptin, Investigational Omarigliptin, and Real-World Data in Patients with Type 2 Diabetes at the 74th Scientific Sessions of the American Diabetes Association
Business Wire - Fri Jun 06, 7:00AM CDT
MSD, known as Merck (NYSE:MRK) in the United States and Canada, will present 13 new studies and analyses, including data for its DPP-4 inhibitor JANUVIA(R) (sitagliptin) and for its investigational once-weekly DPP-4 inhibitor omarigliptin, at the 74th Scientific Sessions of the American Diabetes Association (ADA) being held in San Francisco, June 13-17, 2014. (full story)
Merck to Present New Clinical Data on JANUVIA(R) (Sitagliptin), Investigational Omarigliptin, and Real-World Data in Patients with Type 2 Diabetes at the 74th Scientific Sessions of the American Diabetes Association
Business Wire - Fri Jun 06, 7:00AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, will present 13 new studies and analyses, including data for its DPP-4 inhibitor JANUVIA(R) (sitagliptin) and for its investigational once-weekly DPP-4 inhibitor omarigliptin, at the 74th Scientific Sessions of the American Diabetes Association (ADA) being held in San Francisco, June 13-17, 2014. (full story)
Global Phenylketonuria (PKU) Clinical Trials Report 2014
M2 - Fri Jun 06, 4:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jnxg8w/phenylketonuria) has announced the addition of the "Phenylketonuria (PKU) Global Clinical Trials Review, H1, 2014" report to their offering. Phenylketonuria (PKU) Global Clinical Trials Review, H1, 2014" provides data on the Phenylketonuria (PKU) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Phenylketonuria (PKU). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Phenylketonuria (PKU). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - BioMarin Pharmaceutical Inc. - E. Merck KG - Emory University - University of Leipzig - Washington University School of Medicine - University of Miami - University of Southern California - Ludwig-Maximilians-Universitat Munich - The University of Texas Health Science Center at Houston - Hamilton Health Sciences - University Hospital, Tours - University of Missouri For more information visit http://www.researchandmarkets.com/research/jn...lketonuria (full story)
2 Reasons to Watch Amgen, Inc.
Cory Renauer, The Motley Fool - Motley Fool - Thu Jun 05, 5:30PM CDT
Amgen is looking at two great opportunities. The company's brightest immune-oncology prospect is giving mixed results on its own, but a valuable partnership seems likely. In the race to produce a next-generation cholesterol reducer, high marks from... (full story)
First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily Dosing Regimen of ISENTRESS(R) (raltegravir)
Business Wire - Thu Jun 05, 4:00PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in the company's global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a once-daily investigational formulation of ISENTRESS(R) (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-naive HIV-1-infected adults. ISENTRESS film-coated tablets are currently administered twice daily in accordance with the approved Prescribing Information. (full story)
$100 million NuvaRing settlement finalized
By JIM SALTER - AP - Thu Jun 05, 1:44PM CDT
ST. LOUIS (AP) — A $100 million settlement involving NuvaRing, a birth-control device linked to sometimes-fatal side effects, will stand now that the vast majority of claimants have chosen to opt into the agreement, those involved in the lawsuits said Thursday. (full story)
Merck (MRK) Breaks Through Resistance at $58.12
Comtex SmarTrend(R) - Thu Jun 05, 10:49AM CDT
Shares of Merck (NYSE:MRK) opened today above their pivot of $57.82 and have already reached the first level of resistance at $58.12. Should the shares continue to rise, the resistance pivots of $58.32 and $58.82 will be of interest. (full story)
Germany 2014 Wealth Book - Insights into the $4.2 Trillion Market
M2 - Thu Jun 05, 10:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ls23jl/germany_2014) has announced the addition of the "Germany 2014 Wealth Book" report to their offering. This report is the result of extensive research covering the high net worth individual (HNWI) population and wealth management market in Germany. This report reviews the performance and asset allocations of HNWIs and Ultra-HNWIs in Germany. It also includes an evaluation of the local wealth management market. Scope - Independent market sizing of Germany HNWIs across five wealth bands - HNWI volume, wealth and allocation trends from 2009 to 2013 - HNWI volume, wealth and allocation forecasts to 2018 - HNWI and UHNWI asset allocations across 13 asset classes - Geographical breakdown of all foreign assets - Alternative breakdown of liquid vs. investable assets - Number of UHNWIs in major cities - Number of wealth managers in each city - City wise ratings of wealth management saturation and potential - Details of the development, challenges and opportunities of the Wealth Management and Private Banking sector in Germany - Size of the German wealth management industry - Largest private banks by AuM - Detailed wealth management and family office information - Insights into the drivers of HNWI wealth Key Highlights - There were 1,382,265 HNWIs in Germany in 2013. These HNWIs held US$4.2 trillion in wealth, and wealth per HNWI was US$3,038,491. - In 2013, German HNWI numbers increased by 4.2%, following a 5.7% decrease in 2012. - Growth in HNWI wealth and volumes is expected to improve over the forecast period. The number of German HNWIs is forecast to grow by 11%, reaching 1,561,820 by 2018, and HNWI wealth is expected to grow by 25%, reaching US$5.60 trillion by 2018. - At the end of 2013, German HNWIs held 34.6% (US$1.5 trillion) of their wealth outside their home country, which is higher than the worldwide average of 20-30%. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Wealth Sector Fundamentals 4 Findings from the WealthInsight HNWI Database 5 Analysis of German HNWI Investments 6 Competitive Landscape of the Wealth Sector 7 Appendix Companies Mentioned - BHF-Bank Private Banking - Bankhaus Lampe - Berenberg Private Banking - Commerzbank Private Banking - DZ Privatbank - Deutsche Bank Private Wealth Management - Merck Finck & Co. - Mertzler Private Banking - UniCredit Bank AG For more information visit http://www.researchandmarkets.com/research/ls...rmany_2014 (full story)
Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany
M2 - Thu Jun 05, 9:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4jll46/glioblastoma) has announced the addition of the "Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany" report to their offering. During the 2012-2019 forecast period, the GBM market is expected to grow rapidly from $305m to $583m. Due to the poor prognosis under currently available treatments, therapies with high potency are in strong demand in the Glioblastoma Multiforme (GBM) market. In newly diagnosed patients, the current standard of care, comprising resection surgery, radiation therapy and chemotherapy with Merck's Temodar (temozolomide), has a maximum Overall Survival (OS) of 15 months and almost inevitable tumor recurrence. Current therapeutic options for recurrent GBM are Roche's Avastin (bevacizumab), carmustine and other chemotherapy drugs used off-label. However, they only offer limited OS benefit, leaving high unmet need in this patient segment. The market entry of Northwest Biotherapeutics' DCVax-L, a dendritic cell-based therapeutic vaccine that acts as an add-on to the standard treatment in newly diagnosed patients, will account for much of this growth. Having demonstrated superior OS improvement compared with the standard treatment alone in clinical trials, it is expected to bear high market potential, given that its efficacy is translated into larger Phase III trials. The cancer vaccine Rindopepimut (CDX-110) and targeted therapy Cotara will also enter the GBM market, but will drive growth to a lesser extent. However, unmet needs are likely to remain in the relapsed setting over the forecast period due to the lack of superior OS benefits in the late-stage pipeline. Scope - A brief introduction to GBM, including the disease pathogenesis, risk factors and diagnosis - In-depth analysis of the drugs available for the treatment of GBM, including safety, efficacy, treatment patterns, and strengths and weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy - A comprehensive review of the developmental pipeline for GBM, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period, with the pipeline analyzed by Phase distribution, molecule type and molecular target - Additional in-depth analysis of GBM clinical trials by Phase, molecule type, trial size, trial duration and program failure rate - Multi-scenario forecast data for the GBM market to 2019, taking into account the introduction of new drugs, the expiry of key patents and the changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain - Discussion of the drivers of and barriers to market growth - Discussion of the licensing and co-development deals landscape in GBM Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed drugs - Temodar (temozolomide) - Merck - Avastin (bevacizumab) - Roche - BiCNU (carmustine) and Gliadel Wafer (carmustine in polifeprosan) - BiCNU (carmustine) - Bristol-Myers Squibb - Gliadel Wafer (carmustine in polifeprosan) - Eisai - Lomustine - Carboplatin - Cyclophosphamide - Etoposide - Irinotecan 4 Glioblastoma Pipeline - DCVax-L - Northwest Biotherapeutics - Rindopepimut (CDX-110) - Celldex Therapeutics - Avastin (bevacizumab)- Roche - ICT-107 - ImmunoCellular Therapeutics - Cotara- Peregrine Pharmaceuticals - Eir-060- EirGen Pharma - Heat Map of Safety and Efficacy and Competitor Matrix for Glioblastoma Multiforme Pipeline 5 Market forecasts 6 Deals and Strategic Consolidations - Del Mar Pharmaceuticals Enters into Agreement with Guangxi Wuzhou Pharmaceutical - Immatics Biotechnologies Enters into Agreement with Cancer Research UK - ImmunoCellular Therapeutics Enters into Agreement with University of Pennsylvania - Bexion Pharmaceuticals Enters into Agreement with Cincinnati Children's Hospital Medical Center - Celldex Therapeutics Enters into Agreement with Duke University Brain Tumor Cancer Center 7 Appendix For more information visit http://www.researchandmarkets.com/research/4j...ioblastoma (full story)
Antihypertensive Therapeutics in Major Developed Markets to 2020 - Market to Decline due to Key Patent Expiries
M2 - Thu Jun 05, 9:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tgc6l9/antihypertensive) has announced the addition of the "Antihypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries" report to their offering. Market to Decline due to Key Patent Expiries The global anti-hypertensives market is expected to decline during the forecast period at a negative Compound Annual Growth Rate (CAGR) of 0.9% from $40 billion in 2013 to $37.6 billion in 2020, with growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline thereafter. The initial growth will be due to the increased penetration of fixed-dose combination drugs (Amturnide, Exforge Tribenzor, Azor, Tekturna HCT, Edarbyclor, Twynsta, Benicar HCT, Micardis Plus, Tekamlo, Valturna), a rise in the prevalence population from 181 million to 190 million at a CAGR of 0.6%, and two new expected launches in the pipeline (azilsartan amlodipine, and AHU377 valsartan). However, due to the expiry of the exclusivity of major drugs both before and during the forecast period (Cozaar in 2010; Diovan, Avapro and Atacand in 2012; Exforge in 2014; Benicar in 2016; and Tekturna and Tekturna HCT in 2018), increased generic penetration and a low diagnosis rate, the market will decline from 2017. Hypertension is a chronic disease and so its management required prolonged treatment. The management of hypertension requires prolonged treatment as it is a chronic disease, ultimately ensuring market stability despite generic erosion. Anti-Hypertensives Pipeline: Limited Scope Most of the drugs in the anti-hypertensives pipeline are generics (77%), and only 20% of molecules are novel drug candidates. The novel approach is limited to a few targets such as nondihydropyridine dual L/T-type calcium channel blockers (ACT-280778), Rho-associated kinase inhibitors (AN-3485), and vitamin D receptor agonists (CARD-024), to name a few. Novartis' AHU-377, a novel molecule that functions as a Neutral Endopeptidase Inhibitor (NEP), is currently in Phase III as a combination drug with Novartis' blockbuster valsartan. Most of the drug dosages in the anti-hypertension market comprise one oral tablet once daily. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed Products 4 Product Pipeline 5 Market Forecast 6 Deals and Strategic Consolidations 7 Appendix Companies Mentioned - Boehringer Ingelheim - Daiichi Sankyo - Merck - Novartis - Pfizer - Speedel For more information visit http://www.researchandmarkets.com/research/tg...pertensive (full story)
NuvaRing Lawsuit Attorneys at The Oliver Law Group Comment on CNN Investigation into Alleged NuvaRing Side Effects
PRWeb - Wed Jun 04, 10:31PM CDT
The NuvaRing lawsuit attorneys at The Oliver Law Group note that CNN will air a series of investigative reports detailing the serious, and potentially deadly side effects, allegedly suffered by young women who have used the NuvaRing vaginal ring birth control device. According to an article which appeared in the Durango Herald on June 2, 2014, the series of broadcasts will air during Anderson360, and will feature the family of one young woman who allegedly died after suffering a blood clot brought on by NuvaRing. The young woman's family is now pursuing a NuvaRing lawsuit against Merck & Co., the manufacturer of the contraceptive ring. [cnn.com/video/data/2.0/video/us/2014/06/01/nr-dnt-nuvaring-investigation.cnn.html , CNN June 1, 2014] [durangoherald.com/article/20140602/NEWS01/140609932/-1/taxonomy/Parents-of-young-woman-to-appear-on-CNN-, Durango Herald, June 2, 2014] (full story)
ASCO: Bristol-Myers Squibb and Merck Don't Disappoint
Brian Orelli, The Motley Fool - Motley Fool - Wed Jun 04, 6:38PM CDT
We knew going into American Society of Clinical Oncology annual meeting that immuno-oncology would be a big focus. And Bristol-Myers Squibb and Merck didn't disappoint. Rather than attacking the tumor directly, immuno-oncology drugs encourage... (full story)
Is Merck's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Wed Jun 04, 5:00PM CDT
Merck is one of the world's biggest drugmakers and is a staple in dividend investors' portfolios. That's because pharmaceutical companies such as Merck, Johnson & Johnson , and Bristol-Myers Squibb offer investors a steady (and... (full story)
(0)
(0)Merck & Co. Inc. (MRK) Stock Research Links
Scroll down for more posts ▼